Association between gene expression signatures and outcomes of pembrolizumab (pembro) and paclitaxel (pac) in advanced gastric cancer (GC): Exploratory analysis from KEYNOTE-061
Authors
Shitara, K.Di Bartolomeo, M.
Mandala, M.
Ryu, M. H.
Caglevic, C.
Olesinski, T.
Chung, H. C.
Muro, K.
Goekkurt, E.
McDermott, R. S.
Mansoor, Was
Wainberg, Z. A.
Shih, C. S.
Kobie, J.
Nebozhyn, M.
Cristescu, R.
Cao, Z. A.
Loboda, A.
Ozguroglu, M.
Affiliation
National Cancer Center Hospital East, Chiba, JapanIssue Date
2022
Metadata
Show full item recordCitation
Shitara K, Di Bartolomeo M, Mandala M, Ryu MH, Caglevic C, Olesinski T, et al. Association between gene expression signatures and outcomes of pembrolizumab (pembro) and paclitaxel (pac) in advanced gastric cancer (GC): Exploratory analysis from KEYNOTE-061. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509505169.Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2022-2140Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2022-2140Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2022-2140